The present and future of seizure detection, prediction, and forecasting with machine learning, including the future impact on clinical trials
- PMID: 39055320
- PMCID: PMC11269262
- DOI: 10.3389/fneur.2024.1425490
The present and future of seizure detection, prediction, and forecasting with machine learning, including the future impact on clinical trials
Abstract
Seizures have a profound impact on quality of life and mortality, in part because they can be challenging both to detect and forecast. Seizure detection relies upon accurately differentiating transient neurological symptoms caused by abnormal epileptiform activity from similar symptoms with different causes. Seizure forecasting aims to identify when a person has a high or low likelihood of seizure, which is related to seizure prediction. Machine learning and artificial intelligence are data-driven techniques integrated with neurodiagnostic monitoring technologies that attempt to accomplish both of those tasks. In this narrative review, we describe both the existing software and hardware approaches for seizure detection and forecasting, as well as the concepts for how to evaluate the performance of new technologies for future application in clinical practice. These technologies include long-term monitoring both with and without electroencephalography (EEG) that report very high sensitivity as well as reduced false positive detections. In addition, we describe the implications of seizure detection and forecasting upon the evaluation of novel treatments for seizures within clinical trials. Based on these existing data, long-term seizure detection and forecasting with machine learning and artificial intelligence could fundamentally change the clinical care of people with seizures, but there are multiple validation steps necessary to rigorously demonstrate their benefits and costs, relative to the current standard.
Keywords: deficiency time; epilepsy; human-in-the loop; internet of things; wearables.
Copyright © 2024 Kerr, McFarlane and Figueiredo Pucci.
Conflict of interest statement
WK has received compensation for review articles for Medlink Neurology and consulting for SK Life Sciences, Biohaven Pharmaceuticals, Cerebral Therapeutics, Jazz Pharmaceuticals, EpiTel, UCB Pharmaceuticals, Azurity Pharmaceuticals, and the Epilepsy Study Consortium; and has collaborative or data use agreements with Eisai, Janssen, Radius Health, and Neureka. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- LaFrance WC, Ranieri R, Bamps Y, Stoll S, Sahoo SS, Welter E, et al. Comparison of common data elements from the managing epilepsy well (MEW) network integrated database and a well-characterized sample with nonepileptic seizures. Epilepsy Behav. (2015) 45:136–41. doi: 10.1016/j.yebeh.2015.02.021, PMID: - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
